| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Wien Center for Alzheimer’s Disease and Memory Disorders (Drs. Luis, Loewenstein, Acevedo, and Duara, and W.W. Barker), Mount Sinai Medical Center, Miami Beach; and Departments of Psychiatry and Behavioral Sciences (Drs. Luis, Loewenstein, Acevedo, and Duara) and Medicine (Dr. Duara), University of Miami School of Medicine, FL.
Address correspondence and reprint requests to Dr. Ranjan Duara, Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center/Miami Heart Institute, 4300 Alton Road–MRI building, Miami Beach, FL 33143; e-mail: duara{at}msmc.com
Mild cognitive impairment (MCI), an intermediate state between normal aging and dementia, is characterized by acquired cognitive deficits, without significant decline in functional activities of daily living. Studies conducted on MCI have introduced new concepts regarding the possible distinctions between normal and pathologic aging of the brain. Neuroimaging and genetic testing have aided in the identification of individuals at increased risk for dementia. The measurement of change in cognitive and functional status in MCI remains challenging, because it requires instruments that are more sensitive and specific than those considered adequate for research in dementia. The authors provide an overview of the many methods that have been used to study MCI and directions that may help achieve greater uniformity in methodology. Considerable heterogeneity exists in research methodology used to study the epidemiology, thresholds for cognitive and functional impairment, rate of progression, risk factors, and defining subtypes of MCI. This article emphasizes the need for uniformity in the use of 1) appropriate and sensitive neuropsychological and functional measures to diagnose MCI, 2) reliable methods to determine progression or improvement of cognitive impairment, and 3) instruments in epidemiologic studies to establish population estimates for diverse ethnic and cultural groups. Greater consensus is needed to standardize definitions and research methodology for MCI, so as to make future studies more comparable and more useful for designing effective treatment strategies.
This article has been cited by other articles:
|
|
 |
|
  C. Reitz, R. Mayeux, and J. A. Luchsinger Antihypertensive Medications Influence the Rate of Conversion From Mild Cognitive Impairment to Alzheimer Disease--Reply Arch Neurol, July 1, 2008; 65(7): 995 - 995. [Full Text]
|
|
|
|
|
|
C. Reitz, M.-X. Tang, J. Manly, R. Mayeux, and J. A. Luchsinger Hypertension and the Risk of Mild Cognitive Impairment Arch Neurol, December 1, 2007; 64(12): 1734 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Tyas, J. C. Salazar, D. A. Snowdon, M. F. Desrosiers, K. P. Riley, M. S. Mendiondo, and R. J. Kryscio Transitions to Mild Cognitive Impairments, Dementia, and Death: Findings from the Nun Study Am. J. Epidemiol., June 1, 2007; 165(11): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Luchsinger, C. Reitz, B. Patel, M.-X. Tang, J. J. Manly, and R. Mayeux Relation of Diabetes to Mild Cognitive Impairment Arch Neurol, April 1, 2007; 64(4): 570 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Loewenstein, A. Acevedo, R. Ownby, J. Agron, W. W. Barker, R. Isaacson, S. Strauman, and R. Duara Using Different Memory Cutoffs to Assess Mild Cognitive Impairment. Am J Geriatr Psychiatry, November 1, 2006; 14(11): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Imhof, M. I. Wallhagen, R. Mahrer-Imhof, and A. U. Monsch Becoming forgetful: how elderly people deal with forgetfulness in everyday life. American Journal of Alzheimer's Disease and Other Dementias, October 1, 2006; 21(5): 347 - 353. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Ramani, J. H. Jensen, and J. A. Helpern Quantitative MR Imaging in Alzheimer Disease Radiology, October 1, 2006; 241(1): 26 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Tabert, J. J. Manly, X. Liu, G. H. Pelton, S. Rosenblum, M. Jacobs, D. Zamora, M. Goodkind, K. Bell, Y. Stern, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry, August 1, 2006; 63(8): 916 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Verghese, A. LeValley, C. Derby, G. Kuslansky, M. Katz, C. Hall, H. Buschke, and R. B. Lipton Leisure activities and the risk of amnestic mild cognitive impairment in the elderly Neurology, March 28, 2006; 66(6): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N T Aggarwal, R S Wilson, T L Beck, J L Bienias, and D A Bennett Mild cognitive impairment in different functional domains and incident Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1479 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Nordlund, S Rolstad, P Hellstrom, M Sjogren, S Hansen, and A Wallin The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1485 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Anchisi, B. Borroni, M. Franceschi, N. Kerrouche, E. Kalbe, B. Beuthien-Beumann, S. Cappa, O. Lenz, S. Ludecke, A. Marcone, et al. Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease Arch Neurol, November 1, 2005; 62(11): 1728 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Manly, S. Bell-McGinty, M.-X. Tang, N. Schupf, Y. Stern, and R. Mayeux Implementing Diagnostic Criteria and Estimating Frequency of Mild Cognitive Impairment in an Urban Community Arch Neurol, November 1, 2005; 62(11): 1739 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Ding, W. R. Markesbery, Q. Chen, F. Li, and J. N. Keller Ribosome Dysfunction Is an Early Event in Alzheimer's Disease J. Neurosci., October 5, 2005; 25(40): 9171 - 9175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koontz and A. Baskys Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: A double-blind placebo-controlled study American Journal of Alzheimer's Disease and Other Dementias, September 1, 2005; 20(5): 295 - 302. [Abstract] [PDF]
|
|
|
|
|
|
F. Panza, A. D'Introno, A. M. Colacicco, C. Capurso, A. Del Parigi, R. J. Caselli, A. Pilotto, G. Argentieri, P. L. Scapicchio, E. Scafato, et al. Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes Am J Geriatr Psychiatry, August 1, 2005; 13(8): 633 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Tierney, C. Yao, A. Kiss, and I. McDowell Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years Neurology, June 14, 2005; 64(11): 1853 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Linnebur and J. M. Ruscin Cholinesterase inhibitor use in geriatric outpatients with dementia Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 923 - 926. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Keller, F. A. Schmitt, S. W. Scheff, Q. Ding, Q. Chen, D. A. Butterfield, and W. R. Markesbery Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology, April 12, 2005; 64(7): 1152 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mosconi, D. Perani, S. Sorbi, K. Herholz, B. Nacmias, V. Holthoff, E. Salmon, J.-C. Baron, M. T.R. De Cristofaro, A. Padovani, et al. MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET Neurology, December 28, 2004; 63(12): 2332 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ganguli, H. H. Dodge, C. Shen, and S. T. DeKosky Mild cognitive impairment, amnestic type: An epidemiologic study Neurology, July 13, 2004; 63(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
